Literature DB >> 29571831

Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.

Nicolas A Yannuzzi1, Jayanth Sridhar1, Jonathan S Chang2, James Lin1, Ajay E Kuriyan3, William E Smiddy4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29571831      PMCID： PMC7119243          DOI： 10.1016/j.ophtha.2018.02.019

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  5 in total

1.  Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Authors:  Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

Review 2.  ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.

Authors:  Matthew P Simunovic; David A L Maberley
Journal:  Retina       Date:  2015-10       Impact factor: 4.256

3.  Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.

Authors:  Sobha Sivaprasad; A Toby Prevost; Joana C Vasconcelos; Amy Riddell; Caroline Murphy; Joanna Kelly; James Bainbridge; Rhiannon Tudor-Edwards; David Hopkins; Philip Hykin
Journal:  Lancet       Date:  2017-05-07       Impact factor: 79.321

4.  Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.

Authors:  David W Hutton; Joshua D Stein; Neil M Bressler; Lee M Jampol; David Browning; Adam R Glassman
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

5.  Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.

Authors:  James Lin; Jonathan S Chang; William E Smiddy
Journal:  Ophthalmology       Date:  2016-07-15       Impact factor: 12.079
  5 in total
  1 in total

1.  Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.

Authors:  Hye Kyoung Hong; Young Joo Park; Duk Ki Kim; Na-Kyung Ryoo; You-Jin Ko; Kyu Hyung Park; Ho Min Kim; Se Joon Woo
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.